Recent studies suggested that in vivo CTLA-4 antibodies do not function by blocking CTLA-4 inhibition but by depleting Treg cells in the tumor microenvironment via Fc-receptor mediated mechanisms48. The gene discussed is CTLA4; the disease is neoplasm.